Effect of Liraglutide on Automated Closed-loop Glucose Control in Type 1 Diabetes

NCT01856790 · Completed

Last updated 2026-05-28

This clinical trial tested whether the medication liraglutide helps improve blood sugar control in adults with type 1 diabetes using an automated insulin delivery system.

Status Completed The study has finished.

Phase Early Phase 1 First exploratory testing in people.

Type Interventional (clinical trial)

Design open-label (no blinding) treatment study

Participants 15 people

Who can join Ages 18–40 · all sexes

Timeline Started 2013-02 · est. completion 2015-11

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT01856790 ↗

Description as written by the study sponsor.

"Closed loop artificial pancreas" systems have been under development for the control of blood sugars in those living with diabetes. These systems consist of a continuous glucose sensor, which sends a signal to a computer program that automatically determines how much insulin to give. The computer program then tells an insulin pump to deliver the insulin. While such systems have been tested under a number of conditions, post-meal blood sugars are difficult to control. This study is designed to see if liraglutide, a glucagon like peptide receptor agonist, can help minimize the post meal blood sugar spikes in subjects with type 1 diabetes while they are on a closed loop system.

Treatments tested

ePID closed loop system Device

Insulin pump controlled by closed loop unit and algorithm
liraglutide also known as Victoza Drug

Liraglutide is a long-acting analog of human glucagon like peptide-1 (GLP-1) that works as a GLP-1 receptor agonist

Main thing measured	Peak Post-prandial Venous Glucose Levels
Sponsor	Jennifer Sherr
Conditions studied	Type 1 Diabetes
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01856790 ↗